iterumtx.com (ITRM) - Koefisien utang jangka dawa marang modal

Iterum Therapeutics plc (ITRM) has seen its reputation peak following the success of ORLYNVI. However, geopolitical instability and sanctions are complicating biomaterial logistics and the execution of global trials. The long-term debt-to-equity ratio shows that the metric stands at 0.00, a critical factor to consider as business resilience relies on the market recognition of sulopenem among urologists.

As a portfolio manager, I assess the financial stability of an issuer through its liability structure. This indicator measures the share of long-term borrowings relative to equity, revealing the company's dependence on external financing. Analyzing the ratio of long-term loans to equity allows for the timely detection of rising credit risks. For Iterum Therapeutics plc (ITRM), a low debt level is critical when developing costly antibiotics. This ensures the financial freedom necessary to implement a premium pricing power strategy within the hospital drug market.